β-受体阻滞剂是拮抗β-肾上腺素受体、降低交感神经系统活性的常用药物。新的证据表明，β-受体阻滞剂也可能具有抗癌作用，并有助于克服癌症治疗中的耐药性。这篇综述总结了β-肾上腺素受体不同亚型在癌症进展中的贡献、目前关于β-受体阻滞剂使用与癌症结果之间关系的临床前和临床数据，以及它们增强对化疗和其他标准疗法反应的能力。我们讨论了所提出的机制，包括对血管生成、转移、癌症干细胞和凋亡途径的影响。总体而言，流行病学研究和小型临床试验的结果在很大程度上表明β受体阻滞剂对癌症进展和耐药性具有有益作用。然而，需要更大规模的随机对照试验来确定其临床疗效以及作为癌症治疗辅助药物的最佳利用。© 2024 作者。 FASEB 期刊由 Wiley periodicals LLC 代表美国实验生物学学会联合会出版。

Beta-blockers are commonly used medications that antagonize β-adrenoceptors, reducing sympathetic nervous system activity. Emerging evidence suggests that beta-blockers may also have anticancer effects and help overcome drug resistance in cancer treatment. This review summarizes the contribution of different isoforms of beta-adrenoceptors in cancer progression, the current preclinical and clinical data on associations between beta-blockers use and cancer outcomes, as well as their ability to enhance responses to chemotherapy and other standard therapies. We discuss proposed mechanisms, including effects on angiogenesis, metastasis, cancer stem cells, and apoptotic pathways. Overall, results from epidemiological studies and small clinical trials largely indicate the beneficial effects of beta-blockers on cancer progression and drug resistance. However, larger randomized controlled trials are needed to firmly establish their clinical efficacy and optimal utilization as adjuvant agents in cancer therapy.© 2024 The Author(s). The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.